This is a routine distribution agreement termination. Monitor for any potential revenue impact from the brands after the transition period ends in September 2026, but no immediate trading action is warranted.
RDY drugs
RDY drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Aug 10 $12.15entry
- T+1 · 3mo ago +2.47%α +2.79% · $12.45
- T+5 · 3mo ago −0.33%α −0.28% · $12.11
- T+20 · due 2mo ago Pending
- T+60 · due 14d ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dr. Reddy's terminated a distribution and promotion agreement with Novartis India Limited (NIL) due to a change in NIL's controlling shareholding. The company will continue commercializing the affected brands until September 30, 2026. This is a routine operational update with no material financial impact disclosed.
Key Facts
- Terminated agreement dated February 11, 2022 with Novartis India Limited for distribution and promotion of select brands in India.
- Termination follows a change in controlling shareholding of Novartis India Limited.
- Dr. Reddy's will continue to commercialize the brands until September 30, 2026.
Financial Impact
No financial impact disclosed; immaterial to a $10.2B market cap company.
Risk Factors
- Potential loss of revenue from the brands after September 30, 2026, but likely immaterial given the company's size.
- No further details on the financial contribution of the terminated agreement provided.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (RDY), Batch item 1 | 0001575872-26-000555 |
| Document: 0001575872-26-000555-index.html | 0001575872-26-000555 |
| Document: 0001575872-26-000555.txt | 0001575872-26-000555 |
| 6-K Filing (RDY), Batch item 4 | 0001575872-26-000555 |
| Document: 0001575872-26-000555-index.html | 0001575872-26-000555 |
| Document: 0001575872-26-000555.txt | 0001575872-26-000555 |
Track record
73 reports on RDY
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers